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NucleocapsidWe previously reported that replacing HIV-1 nucleocapsid (NC) domain with SARS-CoV nucleocapsid (N)
residues 2–213, 215–421, or 234–421 results in efﬁcient virus-like particle (VLP) production at a level
comparable to that of wild-type HIV-1. In this study we demonstrate that these chimeras are capable of
packaging large amounts of human APOBEC3G (hA3G), and that an HIV-1 Gag chimera containing the
carboxyl-terminal half of human coronavirus 229E (HCoV-229E) N as a substitute for NC is capable of
directing VLP assembly and efﬁciently packaging hA3G. When co-expressed with SARS-CoV N and M
(membrane) proteins, hA3G was efﬁciently incorporated into SARS-CoV VLPs. Data from GST pull-down
assays suggest that the N sequence involved in N–hA3G interactions is located between residues 86 and 302.
Like HIV-1 NC, the SARS-CoV or HCoV-229E N-associated with hA3G depends on the presence of RNA, with
the ﬁrst linker region essential for hA3G packaging into both HIV-1 and SARS-CoV VLPs. The results raise the
possibility that hA3G is capable of associating with different species of viral structural proteins through a
potentially common, RNA-mediated mechanism.
© 2009 Elsevier Inc. All rights reserved.IntroductionApolipoprotein BmRNA-editing enzyme-catalytic polypeptide-like
3G (APOBEC3G) is a member of the APOBEC3 family of cytidine
deaminases (Cullen, 2006). Human APOBEC3G (hA3G) can be
packaged into HIV-1 virions to mediate C-to-U editing on nascent
proviral minus strands during reverse transcription, resulting in the
inhibition of viral replication (Harris et al., 2003; Mangeat et al., 2003;
Yu et al., 2004; Zhang et al., 2003). Accordingly, hA3G as an anti-viral
factor confers innate immunity to HIV-1. However, HIV-1 encodes Vif,
which counteracts hA3G by inducing hA3G degradation via the
ubiquitin–proteasome pathway, thereby blocking its incorporation
into budding virions (Mehle et al., 2004; Yu et al., 2003). The ability of
Vif to negate hA3G function is both dependent on physical association
and partly species-speciﬁc—in other words, Vif cannot counteract a
form of A3G from a different species. This inefﬁcient Vif–hA3G
interaction means that HIV-1 Vif is capable of counteracting human
and chimpanzee A3G, but not mouse A3G (mA3G) or African green
monkey A3G (Mariani et al., 2003). Other researchers have shown
that hA3G or other APOBEC family members can confer innate
immunity to a wide range of retroviruses as well as HBV (which is
similar to retroviruses in that it also goes through a reverse
transcription step during genomic replication) (Cullen, 2006).
The incorporation of A3G into HIV-1 virions is mediated by the
Gag nucleocapsid (NC) domain (Alce and Popik, 2004; Cen et al.,ll rights reserved.2004; Khan et al., 2005; Luo et al., 2004; Schafer et al., 2004; Zennou
et al., 2004). In addition to playing a key role in viral RNA packaging
(Berkowitz et al., 1993, 1995; Poon et al., 1996; Zhang and Barklis,
1997), NC contains an I domain that is responsible for Gag–Gag
interactions (Bennett et al., 1993; Bowzard et al., 1998). Hetero-
logous polypeptides capable of self-association have been shown to
confer the ability to efﬁciently produce chimeric VLPs when
substituted for HIV-1 NC (Accola et al., 2000; Burniston et al.,
1999; Johnson et al., 2002; Zhang et al., 1998). However, replacing
NC with a leucine-zipper motif that does not encapsidate RNA
abolishes hA3G packaging without signiﬁcantly affecting HIV-1
virion production (Zennou et al., 2004), suggesting RNA involvement
in hA3G incorporation. This is consistent with the proposal that RNA
is required for either hA3G viral incorporation or Gag–hA3G
interaction (Khan et al., 2005; Schafer et al., 2004; Svarovskaia et
al., 2004; Zennou et al., 2004). We previously demonstrated that
HIV-1 Gag mutants containing severe acute respiratory syndrome
coronavirus nucleocapsid (SARS-CoV N) coding sequences as NC
substitutes can effectively assemble VLPs (Wang et al., 2008). While
completely unrelated, the SARS-CoV N protein is similar to HIV-1 NC
in that it contains putative protein–protein interaction domains (He
et al., 2004; Narayanan et al., 2003; Surjit et al., 2004; Yu et al.,
2005) and plays a role in viral RNA packaging (Hsieh et al., 2005;
Huang et al., 2004a).
Given that SARS-CoV N possesses a RNA-binding property, it is
likely that assembly-competent chimeras containing a replacement
of HIV-1 NC by an SARS-CoV N sequence may support the
incorporation of hA3G into VLPs. Here we demonstrate that the
Fig. 1. Schematic representation of chimeric constructs. Shown are mature HIV-1 Gag
protein domain matrix (MA), capsid (CA), nucleocapsid (NC), p6, and amino acid
residues in SP1-NC-SP2 junction. ΔNC has ten HIV-1 NC residues remaining in the
deleted region; ΔPC has NC almost deleted, with SP1 partially removed. delNC has the
two methionine residues (bracketed) in the SP1-NC junction removed. PCR-ampliﬁed
fragments containing various portions of SARS-CoV N coding sequences were inserted
into the deleted NC regions. Numbers denote codon positions at inserted SARS-CoV N
protein sequence boundaries. Arrows indicate SP1-NC and NC-SP2 junction sites.
Remaining HIV-1 NC residues in deleted regions are underlined. Altered or foreign
amino acid residues inserted in juncture area are italicized. All constructs were
expressed in HIVgptD25 (a HIV-1 PR-defective expression vector).
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(HCoV-229E) N protein not only enables efﬁcient VLP production,
but also confers the ability to efﬁciently package human APOBEC3G
(hA3G) when substituted for HIV-1 NC. Direct evidence comes in
the form of hA3G being efﬁciently packaged into SARS-CoV VLPs.
The interaction between coronavirus N and hA3G is also RNA-
dependent. This implies that in addition to retroviruses, SARS-CoV
and other RNA viruses may be capable of packaging hA3G via
nucleocapsid domains.
Results
Interaction between SARS-CoV nucleocapsid protein and
human APOBEC3G
We previously reported that the HIV-1 Gag chimeras containing
the SARS-CoV N carboxyl-terminal 215–421 [NC(N2)] or 234–421 [NC
(N4)] codons in the deleted NC region (Fig. 1) are capable of
assembling VLPs as efﬁciently as wt Gag (Wang et al., 2008). This
raises the question of whether the inserted SARS-CoV N sequence
confers the chimeric ability to package hA3G. We therefore co-
expressed assembly-competent NC(N2) and NC(N4) with hA3G in
293T cells and used Western immunoblotting to detect VLP-
associated hA3G. Our controls were the HIV-1 NC-deleted mutants
ΔNC, ΔPC, and delNC, all with different numbers of deleted NC codons
(Fig. 1). Our results show that NC(N2) and NC(N4) were capable of
packaging hA3G at the same efﬁciency level as the wild-type (Fig. 2A,
lanes 6 and 7 vs. lane 2). Low but detectable VLP-associated hA3G
was observed in the NC-deletion mutants (lanes 4 and 5). Since HIV-1
Vif inhibits hA3G virion incorporation by triggering hA3G degrada-
tion (Conticello et al., 2003; Kao et al., 2003; Liu et al., 2004; Mariani
et al., 2003; Marin et al., 2003; Mehle et al., 2004; Sheehy et al., 2003;
Stopak et al., 2003; Yu et al., 2003), the hA3G expression level or the
presence of Vif may affect the level of virus-associated hA3G. To test
whether Vif or hA3G expression level affects hA3G packaging into
chimeric VLPs, we introduced mutation-blocking Vif expression into
wt and NC(N2) and co-transfected each Vif-deﬁcient (ΔVif) result
with different amounts of the hA3G-coding plasmid. In the absence of
Vif, we observed a relatively higher steady-state hA3G expression
level accompanied by an increased level of VLP-associated hA3G (Fig.
2B, right top panel). Members of the ΔVif group occasionally
expressed higher VLP levels than their Vif-intact counterparts (Fig.
2B, lanes 6–9 vs. 2–5). However, we also repeatedly observed ΔVif
group members producing higher levels of VLP-associated hA3G. In
the presence or absence of Vif, NC(N2) displayed a level of VLP-
associated hA3G comparable to that displayed by wt. These results
suggest that the SARS-CoV N carboxyl-terminal region can be
substituted for HIV-1 NC without affecting VLP assembly or hA3G
packaging functions.
To determine the required SARS-CoV N sequences for conferring
hA3G packaging ability, we co-expressed hA3G with wt or with
chimeras containing a variety of N coding regions as HIV-1 NC
substitutes. As illustrated in Fig. 1, full-length SARS-CoV N sequences
were inserted into the ΔNC (ΔNC[CoN]) and delNC (NC[CoN])
constructs. NC(N1), NC(N3), NC(N5), NC(N6), and NC(N7) respec-
tively contain N codons 2–213, 215–359, 302–421, 2–168, and 2–86 in
the deleted NC region. We again found that both NC(N2) and NC(N4)
were capable of efﬁciently packaging hA3G at VLP-associated hA3G
levels comparable to or higher than those of wt (Fig. 2C, lanes 5 and 7).
Even though ΔNC(CoN) and NC(CoN) were found to be defective in
VLP production, they incorporated hA3G at an efﬁciency level
comparable to that of wt (lanes 2 and 3). Further, despite producing
substantial amounts of VLPs, the NC(N1) was incapable of packaging
hA3G as efﬁciently as wt (i.e., it produced a VLP-associated hA3G level
approximately 60% that of wt) (lane 4). The barely detectable level of
VLP-associated hA3G found in NC(N6) may be due to lower levels ofVLPs in the blot and/or lower levels of hA3G expression (Fig. 2C).
However, in a separate blot containing higher VLP and hA3G
expression levels, VLP-associated hA3G in NC(N6) was approximately
50% that measured in wt (data not shown).
Both hA3G viral incorporation and Gag–hA3G interaction require
the presence of RNA (Khan et al., 2005; Schafer et al., 2004;
Svarovskaia et al., 2004; Zennou et al., 2004). We tested whether
the association between SARS-CoV N and hA3G has the same
requirement by fusing the SARS-CoV N amino-terminal (N1, N6, and
N7) or carboxyl-terminal sequence (N2, and N5) to the carboxyl
terminus of GST and co-expressing each GST fusion construct with
hA3G. Cell lysates containing hA3G and GST fusions were treated with
RNase prior to performing a GST pull-down assay. Results indicate that
GST-CoN, GST-N1, GST-N2, and GST-N6 were capable of pulling down
hA3G, whereas the amount of hA3G associated with GST fusion was
markedly reduced following RNase treatment (Fig. 3). Neither GST-N5
nor GST-N7 was capable of pulling down hA3G, regardless of whether
or not they were treated with RNase (Fig. 3, lanes 7, 9, 16 and 18).
These results suggest that (a) the hA3G-binding domain of SARS-CoV
N is largely contained within the sequence between residues 86 and
302, and (b) efﬁcient N–hA3G interactions occur in a RNA-dependent
manner.
Fig. 2. Incorporation of human APOBEC3G into VLPs. 293T cells were co-transfected with a human APOBEC3G (hA3G) expression vector and indicated plasmid. At 48–72 h post-
transfection, cells and supernatant were collected and subjected to Western immunoblotting. hA3G plasmid DNA (2 or 8 μg) was used for co-transfection as indicated. ΔVif is a Vif-
deﬁcient mutation introduced intowt and NC(N2) (panel B, lanes 6–9). Wild-type Gag and chimeric proteins were probed with a monoclonal antibody directed against HIV-1 CA; an
anti-HA monoclonal antibody was used to detect hA3G. Vif antiserumwas used to detect Vif. Relative levels of VLP-associated hA3G are indicated along the bottom (panel C). hA3G,
wt Gag, and chimeric proteins were quantiﬁed by scanning hA3G and p24CA-associated band densities from immunoblots. Ratios of hA3G to p24gagwere determined and normalized
to that of wt.
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To test whether hA3G can be efﬁciently packaged into SARS-CoV,
we transfected 293T cells containing the hA3G-coding plasmid with
SARS-CoVM andN expression vectors. SARS-CoV VLPswere generated
by co-expressing M and N proteins (Huang et al., 2004b). Results
indicate that the amount of SARS-CoV VLP-associated hA3G was
comparable to that of HIV-1 (Fig. 4A, lane 4 vs. lane 5). Medium hA3Gwas not detected when co-expressed with M or N alone. Extracellular
N was also undetectable without M co-expression (data not shown).
Results from co-immunoprecipitation experiments indicate that N
was capable of associating with hA3G but M was not (data not
shown). The data suggest that hA3G packaging into SARS-CoV VLPs
largely depends on hA3G–N association.
To further conﬁrm an association between released hA3G and
SARS-CoV VLPs formed by M and N, supernatant pellets derived from
Fig. 3. RNase A treatment signiﬁcantly affected SARS-CoV N association with human APOBEC3G. (A) 293T cells were co-transfected with a human A3G (hA3G) expression vector and
pBlueScript SK or indicated GST fusion construct. Cell lysates were subjected toWestern immunoblotting 48 h post-transfection. (B). Equal amounts of cell lysates were treated with
(lanes 10–18) or without (lanes 1–9) 0.2 mg/ml DNase-free RNase A for 30 min at 25 °C, followed by mixing with glutathione-agarose beads for 2 h at 4 °C. Complexes bound to the
beads were pelleted, washed, and subjected to Western immunoblotting with anti-HA and anti-GST antibodies.
Fig. 4. Incorporation of human APOBEC3G into SARS-CoV VLPs. (A) 293T cells were
transfected with hA3G expression vector alone or together with plasmids encoding
SARS-CoV M (membrane) and N, or with the indicated plasmids. At 48–72 h post-
transfection, supernatant and cells were harvested, prepared, and subjected toWestern
immunoblotting. Levels of p24CA-, N-associated proteins and virus-associated hA3G in
each sample were quantiﬁed by scanning immunoblot band densities. Ratios of VLP-
associated hA3G versus p24CA-associated or N-associated protein levels were
calculated for each sample and normalized to that of hA3G associated with wt VLPs
in parallel experiments. (B) Sucrose density gradient fractionation analysis of SARS-CoV
VLPs. 293Tcells were co-transfected with hA3G, M and N expression vectors. At 48–72 h
post-transfection, supernatants were collected and pelleted through 20% sucrose
cushions. Viral pellets were resuspended in PBS buffer and centrifuged through a 20 to
60% sucrose gradient for 16 h. Fractionswere collected from top to bottom,measured for
density and analyzed for hA3G, M, and N proteins level by immunodetection. Densities
of each fraction are indicated on the top.
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subjected to sucrose density gradient fractionation experiments. The
results shown in Fig. 4B indicate that both M and N had fraction 6
peaks at a density of 1.18 g/ml, which is consistent with a previous
report on SARS-CoV virus-like particle density (Huang et al., 2004b). A
hA3G peak was also found at fraction 6, suggesting an association
between hA3G and SARS-CoV VLPs generated via M and N co-
expression.
Mapping the SARS-CoV N-binding domain of human APOBEC3G
Members of the APOBEC3 protein family share a highly conserved
zinc-coordinating motif: His-X-Glu-X23–28-Pro-Cys-X2–4-Cys (Chen
et al., 2007b). Similar to APOBEC1, APOBEC3G contains two zinc-
coordinating motifs, with the carboxyl-terminal zinc-coordinating
motif possessing catalytic cytidine deaminase activity. To identify
hA3G regions responsible for hA3G incorporation into SARS-CoV
VLPs, we co-transfected 293T cells with M and N expression vectors
and a plasmid encoding wt or a hA3G mutant containing various
carboxyl- or amino-terminus deletions (Fig. 5A). The results indicate
that hA3Gmutants lacking residues 1–104,157–384, or 246–384 were
capable of being incorporated into VLPs, and that hA3G mutants
lacking residues 1–156 or 309–384 were undetectable in the medium
samples (Fig. 5B, lanes 4 and 7). In the cases of Δ246–384 and Δ309–
384, poor particle incorporation may be due in part to low expression
levels. In particular, Δ309–384 was barely detectable in repeat
experiments. Low steady-state expression levels of the carboxyl-
terminal truncated hA3G mutant have been reported previously (Cen
et al., 2004). In comparison, the Δ157–384 mutant expressed greater
steady-state stability and a higher level of VLP-associated hA3G (lanes
5 and 12). To test whether the mutations had similar effects on hA3G
packaging into chimeric VLPs, wt or each hA3G mutant was
individually co-expressed with NC(NC2) (which contains the
carboxyl-terminal half of the N coding sequence and is known to
efﬁciently produce VLPs and package hA3G) (Figs. 1 and 2). Our
results indicate that the hA3G mutations exerted similar effects on
hA3G packaging into NC(N2) VLPs with no detectable VLP-associated
Δ1–156 or Δ309–384 (Fig. 5C).
Combined, these results suggest that the essential region for hA3G
packaging into SARS-CoV VLPs is located between residues 104 and
156, corresponding to the ﬁrst linker region. To test whether the
deletion mutations exerted similar effects on hA3G incorporation into
HIV-1 VLPs, we co-expressed wt or each hA3G deletion mutant
Fig. 5. Incorporation of human APOBEC3G into VLPs. (A) Schematic representatives of wt and human APOBEC3G (hA3G) expression constructs. Open boxes indicate the zinc-
coordinating motif, HXE-X23–28-CX2–4C. The asterisk denotes the cytidine deaminase catalytic site. Domains that previously referred to the “linker” peptides are depicted by
arrowheads. Numbers denote amino acid positions in hA3G. Indicated positions of deleted hA3G amino acid residue boundaries were used to designatemutant hA3G constructs. Note
that each hA3G deletion mutant was tagged with a single copy of HA at the carboxyl terminus and that the wt hA3G was triple-tagged with HA. This may have caused a higher signal
for the detected wt hA3G, thus leading to underestimates of the VLP-associated hA3G deletion mutants. (B–D) Incorporation of wt and mutant hA3G into VLPs. 293T cells were co-
transfected with M and N, NC(N2) or an HIV-1 Gag expression vector (HIVgptD25) plus each of the hA3G expression vectors. To avoid effects from Vif on hA3G expression level, NC
(N2) and HIVgptD25 were expressed in Vif-deﬁcient (ΔVif) contexts. At 48–72 h post-transfection, supernatant and cells were harvested, prepared, and subjected to Western
immunoblotting. M and N were probed with M antiserum and an anti-N monoclonal antibody. hA3G was probed with an anti-HA antibody and wt Gag and chimeric proteins were
detected with an anti-p24CA antibody. Levels of p24CA- and N-associated proteins and virus-associated hA3G in each sample were quantiﬁed by scanning immunoblot band
densities. Ratios of total hA3G versus p24CA-associated or N-associated protein levels were calculated for each sample and normalized to that of wt hA3G in parallel experiments.
Dashes (–) denote ratios below 0.01. Similar results were observed in repeat and independent experiments. The immunoblots presented here were intentionally overexposed to
allow for visualization of the individual hA3G mutants.
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et al., 2004; Luo et al., 2004), the Δ1–156 mutation (with a deletion
involving the ﬁrst linker region) blocked hA3G incorporation (Fig. 5D,
lane 4). Overall, the deletion mutations had similar effects on hA3G
packaging into HIV-1, NC(N2), and SARS-CoV VLPs. Speciﬁcally, the
essential domain for incorporating hA3G into HIV-1 and SARS-CoV
VLPs was located in the same (ﬁrst) linker region.
Association between human coronavirus 229E nucleocapsid protein
and hA3G
To test whether the SARS-CoVN ability to confer hA3G packaging is
dependent on N–hA3G interaction and therefore distinct from its self-
interaction capacity, we co-expressed hA3G with an assembly-
competent Gag containing a leucine-zipper domain as a NC substitute.
Inserting a wild-type leucine-zipper (wtZiP) domain into the deleted
NC region restored VLP production to wt level (Fig. 6A, lane 4). A
mutant leucine-zipper motif (KZiP) replacement was incapable of
rescuing the ΔNC assembly defect (Fig. 6A, lane 5), but in spite of
producing awt-comparable level of VLPs,ΔNC(wtZiP) did not package
hA3G as efﬁciently as wt (lane 4 vs. lane 2).
We also examinedwhether human coronavirus 229E (HCoV-229E)
N protein (having approximately 30% homology with SARS-CoV N at
the amino acid level) (Tswen-Kei Tang, 2005) is capable of conferringthe ability to package hA3G when substituted for HIV-1 NC. To
perform this test, we constructed NC(229EN2) (an NC[N2] counter-
part) by inserting the HCoV-229E carboxyl-terminal half nucleocapsid
coding sequence into the deleted HIV-1 NC region. The resulting
construct was transiently co-expressed with hA3G in 293T cells. The
results indicate that NC(229EN2) can also package hA3G to a degree
comparable to that of wt when released VLPs are at a similar level
(data not shown). To mitigate the impact of overexpressed hA3G on
this conclusion, we repeated the experiment by co-expressing hA3G
with wt or the chimeric construct in 293 cells. As the results in Fig. 6B
indicate, the carboxyl-terminal half of HCoV-229E N (which also
contains a putative self-association domain) (Tswen-Kei Tang, 2005)
was capable of replacing the HIV-1 NC function with respect to VLP
assembly and hA3G packaging—that is, substantial amounts of VLPs
and hA3G were detected in NC(229EN2) transfectant supernatant
(lane 4). To determine whether the interaction between hA3G and
HCoV-229E N also requires RNA, we performed a GST pull-down assay
in the presence or absence of RNase. As expected, the GST fusions
containing the full-length (GST-229EN), amino-terminal half (GST-
229EN1), or carboxyl-terminal half (GST-229EN2) of the HCoV-229E
N sequence were capable of efﬁcient hA3G pull-down, which is also
dependent on the presence of RNA (Fig. 7). These data suggest that
HCoV-229E N and SARS-CoV N may share a propensity for hA3G-
association.
Fig. 7. Association of HCoV-229E nucleocapsid protein with hA3G. (A) 293T cells were
co-transfected with a human A3G (hA3G) expression vector and pBlueScript SK, GST, or
GST fusions encoding the full-length (GST-229EN), amino-terminal (GST-229EN1) or
carboxyl-terminal (GST-229EN2) half of HCoV-229E nucleocapsid protein. Cell lysates
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Any conclusion that SARS-CoV N enables efﬁcient hA3G packaging
into VLPs when substituted for HIV-1 NC must be tempered when
over-expression systems are considered. Still, the evidence presented
in this paper suggests an association between SARS-CoV N and hA3G—
that is, the leucine-zipper domain is incapable of conferring the ability
to package hA3G when substituted for HIV-1 NC even though it
enables efﬁcient VLP production. Moreover, assembly-competent
chimeras with various SARS-CoV N protein sequences inserted into
the deleted HIV-1 NC did not have equal hA3G packaging capabilities:
NC(N2) and NC(N4) exhibited a higher level of VLP-associated hA3G
than NC(N1). Results from a GST pull-down assay suggest that the
SARS-CoV N domain associated with hA3G is largely contained within
the central N region between residues 86 and 302 (Fig. 3). Although
GST-N1 and GST-N6 can pull down hA3G, we found that NC(N1) and
NC(N6) are incapable of packaging hA3G as efﬁciently as wt or NC
(N2). Therefore, insufﬁcient hA3G incorporation into NC(N1) and NC
(N6) may be due in part to steric hindrance in a chimeric protein
context.
Evidence that a carboxyl-terminal self-association domain of
SARS-CoV N or HCoV-229E N (as opposed to the amino-terminalFig. 6. Incorporation of hA3G into chimeric VLPs. 293T (panel A) or 293 (panel B) cells
were co-transfected with a human APOBEC3G (hA3G) expression vector and indicated
plasmid. ΔNC(wtZiP) and ΔNC(KZiP) contained HIV-1 NC replacements consisting of
wild-type or a mutated version of a leucine-zipper domain, respectively. NC(229EN2)
contained the carboxyl-terminal half of a 229E human coronavirus nucleocapsid as a
replacement for HIV-1 NC. At 48–72 h or 72 h (panel B) post-transfection, cells and
supernatant were collected and subjected to Western immunoblotting. Wild-type Gag
and chimeric proteins were probed with a monoclonal antibody directed against HIV-1
CA or SARS-CoV N; an anti-HA monoclonal antibody was used to detect hA3G.
were subjected to Western immunoblotting 48 h post-transfection. (B) Equal amounts
of cell lysates were treated with (lanes 6–10) or without (lanes 1–5) 0.2 mg/ml DNase-
free RNase A, followed by GST pull-down assay as described in the legend of Fig. 3.RNA-binding domain) confers the ability to efﬁciently package hA3G
suggests that for this speciﬁc purpose, HIV-1 NC can be replaced by a
protein sequence that does not encapsidate HIV-1 genomic RNA.
Given the number of studies demonstrating that viral genomic RNA is
dispensable for efﬁcient A3G packaging (Alce and Popik, 2004; Cen et
al., 2004; Khan et al., 2005; Luo et al., 2004; Navarro et al., 2005;
Schafer et al., 2004; Svarovskaia et al., 2004; Zennou et al., 2004), any
genomic RNA packaging defect that does exist should not exert a
signiﬁcant impact on the hA3G package. The ﬁnding that efﬁcient
SARS-CoV N association with hA3G is RNA-dependent (Fig. 3) agrees
with the proposal that RNA (viral or nonspeciﬁc) is required for
mediating hA3G–Gag association and hA3G incorporation into virions
(Svarovskaia et al., 2004; Zennou et al., 2004). We assumed that the
chimeras considered competent in hA3G packaging are capable of
packaging considerable amounts of RNA, since the SARS-CoV N (Hsieh
et al., 2005; Luo et al., 2006) and HIV-1 MA domains (Burniston et al.,
1999; Ott et al., 2005) both possess nucleic acid binding properties
that may confer RNA packaging ability. Using a RNA quantiﬁcation
assay as described by Chang et al. (2008), we found that NC(N2) VLPs
contain RNA at approximately 80% of the level measured in HIV-1 Gag
VLPs (data not shown).
Recent studies have suggested that hA3G preferentially binds with
cellular 7SL RNA, which in turn facilitates an association between
RNA-bound hA3G and NC for viral incorporation (Bogerd and Cullen,
2008; Wang et al., 2007). Accordingly, 7SL RNA apparently plays a key
role in determining hA3G packaging into HIV-1 virions. Additional
experiments are required to determine whether SARS-CoV or NC(N2)
are as capable as HIV-1 in terms of packaging 7SL RNA. To date, one in
vitro study has demonstrated that A3G binds to RNA prior to HIV-1 NC
association (Bogerd and Cullen, 2008). Accordingly, it may be that the
interactions required for A3G/RNA/NC ternary complex formation
involve speciﬁc contacts between NC and both A3G and A3G-bound
RNA. SARS-CoV N association with hA3G may in large part depend on
N binding to hA3G-bound RNA, since the SARS-CoV N contains
clusters of basic residues in the amino- and carboxyl-terminal regions
that may confer RNA-binding ability (Hsieh et al., 2005). Extensive
genetic analyses indicate that SARS-CoV N RNA-binding domains are
largely located between amino acid residues 45–181 (Huang et al.,
2004a), 248–280 (Chen et al., 2007a; Luo et al., 2006), and 363–382
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residues. It is conceivable that basic residue clusters within SARS-CoV
Nmake a signiﬁcant contribution to hA3G–N association by enhancing
N binding to hA3G-associated RNA. Compatible with this hypothesis,
we found that the GST fusions GST-CoN, GST-N1, GST-N2 and GST-N6,
all of which contain most of the residues involved in RNA-binding, are
competent in their associations with hA3G (Fig. 3). The exception to
this rule is GST-N5, which is unable to pull down hA3G despite bearing
a putative RNA-binding domain (residues 363–382). Our ﬁnding that
the essential region for hA3G packaging into HIV-1 or SARS-CoV VLPs
resides between codons 104 and 156 is compatible with a genetic
analysis demonstrating that residues 124 to 127 are responsible for
hA3G viral incorporation (Huthoff and Malim, 2007).
A very recent study suggests that hA3G contains a necessary and
sufﬁcient cytoplasmic retention signal located between residues 113
and 128 (Bennett et al., 2008). Consistent with this report, our
immunoﬂuorescence experiment results indicate that cells expressing
the hA3G deletion mutant Δ1–156 show ﬂuorescence staining in both
the nucleus and cytoplasm; in contrast, ﬂuorescence in cells
expressing wt or hA3G mutants Δ1–104, Δ157–384, or Δ246–384 is
predominantly present in cell cytoplasm (data not shown). However,
the mislocalization of Δ1–156 does not account for its defective
incorporation into HIV-1 or SARS-CoV VLPs, since GST pull-down
assay results suggest that cytoplasmic hA3G(Δ1–156) is still incapable
of associating with SARS-CoV N (data not shown).
HCoV-229E N and SARS-CoV N share two conserved sequences:
one from residues 50 to 170 and the other from 250 to 360 (Tswen-Kei
Tang, 2005). Combined, the ability of NC(229EN2) to package hA3G
and the RNA-dependent association of HCoV-229E N with hA3G
(Fig. 7) imply that in addition to SARS-CoV N, coronaviral N products
may associate with hA3G via binding with RNA. However, human T-
cell leukemia virus type 1 (HTLV-1) has been found to prevent hA3G
packaging through Gag NC domain action (Derse et al., 2007),
suggesting that some RNA viruses are incapable of packaging A3G.
Our results indicate that the presence of the hA3G ﬁrst linker region is
required for hA3G to be packaged into either HIV-1 Gag or SARS-CoV
VLPs. It is possible that an RNA/hA3G complex, either alone or in
combination with other cellular factors, is an acceptable structure for
an association between HIV-1 NC and SARS-CoV N.
Here we demonstrated for the ﬁrst time that SARS-CoV is capable
of packaging hA3G via the SARS-CoV N protein. It remains to be
determined whether chimeric NC(N2) or SARS-CoV can package
endogenous A3G as efﬁciently as HIV-1. The biological signiﬁcance of a
SARS-CoV N association with hA3G also requires further exploration.
According to one report, hA3G is capable of editing virus-associated
HIV-1 RNA (Bishop et al., 2004); the hA3G-mediated inhibition of viral
replication may be independent of its cytidine deaminase activity
(Rösler et al., 2005; Turelli et al., 2004). Since humans are not natural
hosts for SARS-CoV (Li et al., 2005), human susceptibility implies that
cells infected by SARS-CoV may not express A3G, or SARS-CoV may
have evolved to counteract A3G anti-viral activity. Further studies are
required to address this issue.
Materials and methods
Plasmid construction
The parental HIV-1 proviral plasmid DNA used in this study was
HXB2 (Ratner et al., 1985). The cDNA clone of the SARS-CoV N (SARS
coronavirus strain TWC, GenBank accession number AY321118) was
provided by the Centers for Disease Control of the Department of
Health, Taiwan. HIV-1 NC-deletion mutants ΔNC, delNC, and ΔPC and
chimeras ΔNC(CoN), NC(CoN), NC(N1), NC(N2), NC(N3), NC(N4), NC
(N5), NC(N6), NC(N7), ΔNC(wtZiP) and ΔNC(KZiP) were all as
previously described (Wang et al., 2008). Primers used for making
NC(229EN2) were 5′-CGCAATCGATTCATGAAGGCAGTTGCT-3′ (for-ward) and 5′-CTTCGGATCCCGTTTACTTCATCAAT-3′ (reverse) using a
coronavirus 229E (HCoV-229E) nucleocapsid expression vector pTRE-
HN (Schelle et al., 2005) as template (kindly provided by Volker
Thiel). To construct a Vif-deﬁcient (ΔVif) mutation, Vif-encoding
plasmid DNAwas digestedwith NdeI, ﬁlled in, and relegated, resulting
in a shift in the Vif open reading frame. All of the engineered
constructs were cloned into the PR-defective HIV-1 proviral expres-
sion vector HIVgptD25 (Wang et al., 2000). Human APOBEC3G (hA3G)
expression vector pcDNA3.1-APOBEC3G-HA (Sheehy et al., 2002;
Stopak et al., 2003) was obtained through the NIH AIDS Research and
Reference Reagent Program. hA3G deletion mutants were gifts from S.
Cen (Cen et al., 2004). Mammalian expression vectors encoding SARS-
CoV M and N were provided by G.J. Nabel (Huang et al., 2004b).
To construct GST fusions, amplicons containing SARS-CoV N or
HCoV-229E N coding sequences were digested with BamHI and ClaI
and fused to the C-terminus of GST, which is directed by a mammalian
elongation factor 1a promoter (Cortes et al., 1996). Primers for cloning
GST fusions were GST-CoN, 5′-TAAAGGATCCTCTGATAATGGACCC-3′
(forward), 5′-TCATATCGATTTATGCCTGAGTTGAATC-3′ (reverse); GST-
N1, 5′-TAAAGGATCCTCTGATAATGGACCC-3′ (forward), 5′-GCTCAT-
CGATTAGCTAGCCATTCGAGC-3′ (reverse); GST-N2, 5′-TGGCTGGAT-
CCGGTGGTGAAACTGCC-3′ (forward), 5′-TCATATCGATTTATGCCT-
GAGTTGAATC-3′ (reverse); GST-N5, 5′-ATTACGGATCCTGGCCG-
CAAATTGCA-3′ (forward), 5′-TCATATCGATTTATGCCTGAGTTGAATC-3′
(reverse); GST-N6, 5′-TAAAGGATCCTCTGATAATGGACCC-3′ (forward),
5′-GCTCATCGATTATGTTGTTCCTTGAGG-3′(reverse); GST-N7, 5′-
TAAAGGATCCTCTGATAATGGACCC-3′ (forward), 5′-GCTCATCGAT-
TAGCCAATTTGGTCAT-3′ (reverse); GST-229EN, 5′-CGGGATCCGCTA-
CAGTCAAATGG-3′ (forward), 5′-CCATCGATTAGTTTACTTCATCAAT-3′
(reverse); GST-229EN1, 5′-CGGGATCCGCTACAGTCAAATGG-3′ (for-
ward), 5′-CCATCGATTATTCCTGAGGCTTGTC-3′ (reverse); and GST-
229EN2, 5′-CGGGATCCATGAAGGCAGTTGCT-3′ (forward), 5′-CCATC-
GATTAGTTTACTTCATCAAT-3′ (reverse). Mutations were conﬁrmed by
restriction enzyme digestion or DNA sequencing.
Cell culture and transfection
293T and 293 cells were maintained in Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 10% fetal calf serum (GIBCO).
Conﬂuent 293T or 293 cells were trypsinized and split 1:10 onto 10-
cm dishes 24 h prior to transfection. For each construct, cells were
transfected with 20 μg of plasmid DNA using the calcium phosphate
precipitation method; 50 μm chloroquine was added to enhance
transfection efﬁciency. Unless otherwise indicated, 10 μg of each
plasmid was used for co-transfection. Culture supernatant and cells
were harvested for protein analysis 2–3 d post-transfection.
Western immunoblot
At 48–72 h post-transfection, supernatant from transfected 293T
or 293 cells was collected, ﬁltered, and centrifuged through 2 ml of
20% sucrose in TSE (10 mM Tris–HCl [pH 7.5], 100 mM NaCl, 1 mM
EDTA plus 0.1 mM phenylmethylsulfonyl ﬂuoride [PMSF]) at 4 °C for
40 min at 274,000 ×g. Pellets were suspended in IPB (20 mM Tris–HCl
[pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 0.5% sodium
deoxycholate, 1% Triton X-100, 0.02% sodium azide) plus 0.1 mM
PMSF. Next, cells were rinsed with ice-cold phosphate-buffered saline
(PBS), collected in IPB plus 0.1 mM PMSF, andmicrocentrifuged at 4 °C
for 15 min at 13,700 ×g to remove cell debris. Supernatant and cell
samples were mixed with equal volumes of 2X sample buffer
(12.5 mM Tris–HCl [pH 6.8], 2% SDS, 20% glycerol, 0.25% bromophenol
blue) and 5% β-mercaptoethanol and boiled for 5 min. Samples were
resolved by electrophoresis on SDS-polyacrylamide gels and electro-
blotted onto nitrocellulose membranes. Membrane-bound Gag or
chimeric proteins were immunodetected using a mouse monoclonal
antibody directed against HIV-1 p24CA (Wang et al., 1998) or the
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detected with a rabbit anti-M polyclonal antibody (Rockland). HA-
tagged hA3G was probed with a mouse anti-HA (Sigma) monoclonal
antibody at a dilution of 1:5000. For HIV-1 Vif detection, a rabbit anti-
Vif polyclonal antibody (Goncalves et al., 1994) was used at a 1:2000
dilution. The secondary antibody was a sheep anti-mouse or donkey
anti-rabbit horseradish peroxidase-(HRP) conjugated antibody (Invi-
trogen), both at 1:5000 dilutions. To detect GST and GST fusions, anti-
GST HRP conjugate (Amersham) was used at a 1:5000 dilution.
Horseradish peroxidase activity was detected according to the
manufacturer's protocol.
GST pull-down assay
293T cells either mock transfected or transfected with GST fusion
expression vectors were collected, lysed in RIPA buffer (140 mM NaCl,
8 mMNa2HPO4, 2 mMNaH2PO4, 1% NP-40, 0.5% sodium deoxycholate,
0.05% SDS) containing complete protease inhibitor cocktail (Roche),
and microcentrifuged at 4 °C for 15 min at 13,700 ×g (14,000 rpm) to
remove cell debris. Aliquots of post-nuclear supernatant (PNS) were
mixed with equal amounts of 2× sample buffer and 5% β-mercap-
toethanol and held forWestern blot analysis. RIPA buffer was added to
the remaining PNS samples to ﬁnal volumes of 500 μl. Each sample
was mixed with glutathione-agarose beads (30 μl) (Sigma) and
rocked for 2 h at 4 °C. Bead-bound complexes were pelleted, washed
tree times with RIPA buffer, twicewith PBS, eluted at 1× sample buffer
with 5% β-mercaptoethanol, boiled for 5 min, and subjected to SDS-
10% PAGE as described above.
Sucrose density gradient fractionation
Supernatant cultures of transfected 293T cells were collected,
ﬁltered, and centrifuged through 2 ml 20% sucrose cushions as
described above. Viral pellets were suspended in PBS buffer and laid
on top of a pre-made 20–60% sucrose gradient consisting of 1 ml
layers of 20, 30, 40, 50 and 60% sucrose in TSE that had been allowed to
sit for 2 h. Gradients were centrifuged in an SW50.1 rotor at
40,000 rpm (274,000 ×g) for 16 h at 4 °C; 500 μl fractions were
collected from top to bottom. Sucrose density was measured for each
fraction. Proteins in each fraction were precipitated with 10%
trichloroacetic acid (TCA) and subjected to Western immunoblotting.
Laser scanning immunoﬂuorescence microscopy
Conﬂuent 293 cells were split 1:80 onto coverslips 24 h before
transfection. Two days post-transfection, cells were ﬁxed at 4 °C for
20 min with ice-cold PBS containing 3.7% formaldehyde, washed
once with PBS and once with DMEM plus 10% heat-inactivated calf
serum (DMEM/calf serum), and permeabilized at room temperature
for 10 min in PBS plus 0.2% Triton X-100. Samples were incubated
with the primary antibody for 1 h and secondary antibody for
30 min. Following each incubation, samples were subjected to three
washes (5 to 10 min each) with DMEM/calf serum. The primary
antibody was an anti-HA (Sigma) at a 1:200 dilution. A rabbit anti-
mouse rhodamine-conjugated antibody at a 1:100 dilution served as
the secondary antibody (Cappel, ICN Pharmaceuticals, Aurora, Ohio,
USA). After the ﬁnal DMEM/calf serum wash, the coverslips were
washed three times with PBS and mounted in 50% glycerol in PBS for
viewing. Images were taken using an epiﬂuorescence microscope
(Olympus AX-80) or laser scanning confocal microscope (Olympus
FV300).
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